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IL-22 is a member of the IL-10 cytokine family 
and plays critical roles in inflammation, immune 
surveillance, and tissue homeostasis at mucosal 
sites (Ouyang et al., 2008; Colonna, 2009). IL-22 
is produced by CD4+ Th17 cells, NK cells, 
CD11c+ myeloid cells, and lymphoid tissue   
inducer–like cells (Liang et al., 2006; Zheng et al., 
2008; Cella et al., 2009; Takatori et al., 2009). 
The IL-22 receptor is composed of the IL-22R 
and IL-10R2 subunits, and receptor ligation re-
sults in phosphorylation of STAT1, STAT3, 
and STAT5 and activation of the p38 mitogen- 
activated protein kinase pathway (Kotenko et al., 
2001; Lejeune et al., 2002). The IL-22 receptor 
is found on cells of nonhematopoietic origin in 
the skin, kidney, liver, lung, and gut, allowing 
for IL-22–mediated regulation of local epithe-
lial, endothelial, and stromal cell responses after 
infection or exposure to inflammatory stimuli 
(Wolk et al., 2004; Ouyang et al., 2008). De-
spite significant insights into IL-22–IL-22R in-
teractions, reports on the in vivo functions of 
this pathway have been conflicting (Zenewicz 
and Flavell, 2008). For example, after infection 
with Gram-negative bacteria, IL-22 can enhance 
maintenance of the epithelial barrier and act in 
CORRESPONDENCE  
David Artis:  
dartis@vet.upenn.edu
Abbreviations used: BAL,  
bronchioalveolar lavage;   
RT-PCR, real-time PCR; 
TUNEL, terminal deoxynucle-
otidyl trasferase dUTP  
nick-end labeling.
G.F. Sonnenberg and M.G. Nair contributed equally to this 
paper.
T.J. Kirn’s present address is the University of Medicine and 
Dentistry of New Jersey, Newark, NJ 07103.
C. Zaph’s present address is the Biomedical Research  
Centre, University of British Columbia, Vancouver,  
BC V6T 1Z3, Canada.
Pathological versus protective functions  
of IL-22 in airway inflammation are 
regulated by IL-17A
Gregory F. Sonnenberg,1 Meera G. Nair,1 Thomas J. Kirn,1 Colby Zaph,1 
Lynette A. Fouser,2 and David Artis1
1Department of Pathobiology, University of Pennsylvania, Philadelphia, PA 19104
2Inflammation and Immunology–Pfizer BioTherapeutics Research and Development, Cambridge, MA 02140
IL-22 has both proinflammatory and tissue-protective properties depending on the context 
in which it is expressed. However, the factors that influence the functional outcomes of  
IL-22 expression remain poorly defined. We demonstrate that after administration of a high 
dose of bleomycin that induces acute tissue damage and airway inflammation and is lethal 
to wild-type (WT) mice, Th17 cell–derived IL-22 and IL-17A are expressed in the lung. 
Bleomycin-induced disease was ameliorated in Il22/ mice or after anti–IL-22 monoclonal 
antibody (mAb) treatment of WT mice, indicating a proinflammatory/pathological role for 
IL-22 in airway inflammation. However, despite increased bleomycin-induced IL-22 produc-
tion, Il17a/ mice were protected from airway inflammation, suggesting that IL-17A may 
regulate the expression and/or proinflammatory properties of IL-22. Consistent with this, 
IL-17A inhibited IL-22 production by Th17 cells, and exogenous administration of IL-22 
could only promote airway inflammation in vivo by acting in synergy with IL-17A. Anti– 
IL-22 mAb was delivered to Il17a/ mice and was found to exacerbate bleomycin-induced 
airway inflammation, indicating that IL-22 is tissue protective in the absence of IL-17A. 
Finally, in an in vitro culture system, IL-22 administration protected airway epithelial cells 
from bleomycin-induced apoptosis, and this protection was reversed after coadministration 
of IL-17A. These data identify that IL-17A can regulate the expression, proinflammatory 
properties, and tissue-protective functions of IL-22, and indicate that the presence or 
absence of IL-17A governs the proinflammatory versus tissue-protective properties of IL-22 
in a model of airway damage and inflammation.
© 2010 Sonnenberg et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Nagai et al., 1992; Huaux et al., 2003; Matute-Bello et al., 
2008). These responses have been shown to be partially depen-
dent on both T cells and the cytokines IL-6 and IL-12/23p40, 
as depletion or genetic deletion of any of these factors individ-
ually attenuates bleomycin-induced disease (Maeyama et al., 
2001; Sakamoto et al., 2002; Saito et al., 2008). Expression of 
IL-6 and IL-12/23p40 also promotes Th17 cell differentiation 
and survival (Bettelli et al., 2006; Mangan et al., 2006; 
McGeachy et al., 2009). However, whether Th17 cells differ-
entiate and extravasate to the lung after an instillation of high-
dose bleomycin is unknown.
To test this, either PBS or a high dose of bleomycin that is 
lethal for WT mice was intratracheally instilled into C57BL/6 
mice, and mRNA isolated from whole lung tissue was ana-
lyzed for cytokines associated with Th17 cell differentiation. 
Although levels of Il6, Tgfb1, and Il12b were not significantly 
increased, Il23a transcript was significantly elevated in samples 
from bleomycin-instilled mice compared with PBS controls 
(Fig. S1). Consistent with no significant changes in Tgfb1 
mRNA, no up-regulation of active TGF- protein could be 
observed in the lung tissue of mice receiving a high dose of 
bleomycin, as determined by ELISA (Fig. S2 A) or immuno-
fluorescence staining (Fig. S2 B), in comparison to PBS- 
instilled controls. Furthermore, increased active TGF- protein 
could only be observed in the lungs of mice receiving a low 
dose of bleomycin, which is known to induce lung fibrosis 
(Fig. S2, A and B).
An increase in mRNA encoding the Th17 effector cyto-
kines Il17a and Il22 was observed in the lungs of bleomycin-
instilled mice (Fig. 1 A). However, bleomycin-induced 
inflammation was not associated with expression of IL-17F, as 
IL-17F could not be detected in the lungs by real-time PCR 
(RT-PCR; not depicted) or intracellular staining (Fig. S3 A) 
compared with in vitro differentiated Th17 cells (Fig. S3 B).
A previous study reported that after high-dose bleomycin 
instillation, TCR+ cells were a dominant source of IL-17A 
(Braun et al., 2008). To identify the cellular sources of IL-17A 
after bleomycin exposure, lung cell suspensions from bleomy-
cin-instilled C57BL/6 mice were isolated, stimulated briefly 
ex vivo, and analyzed by flow cytometry for surface markers 
and intracellular cytokines. Although 21% of the total IL-17A+ 
cells were found to be TCR+ cells, TCR+ cells constituted 
65% of the total IL-17A+ cells (Fig. 1 B, top left and middle). 
The majority of TCR+ cells that expressed IL-17A were 
CD4+, indicating that bleomycin induced a dominant CD4+ 
TCR+ Th17 cell response (Fig. 1 B, top right). Although 
unclear at present, differences in local environment stimuli, 
origin of mice, or the source, dose, and kinetics of adminis-
tered bleomycin may contribute to whether TCR+ or 
TCR+ T cells are the dominant sources of IL-17A in the 
airway after bleomycin exposure. Analysis of IL-22+ cell popu-
lations  revealed  that  predominantly  CD4+  TCR+  T  cells 
produced IL-22 after bleomycin exposure (Fig. 1 B, bottom). 
Although these data do not definitively rule out other cellular 
sources of IL-17A and IL-22, they indicate that CD4+ TCR+ 
T cells are the dominant source of both cytokines after   
synergy with the Th17 cell–coexpressed cytokine IL-17A to 
promote host protective immunity against infection (Liang et al., 
2006; Aujla et al., 2008; Zheng et al., 2008). In addition to   
antimicrobial properties, several studies have reported tissue-
protective properties of IL-22 in mouse models of inflamma-
tory bowel disease and hepatitis (Pan et al., 2004; Radaeva   
et al., 2004; Zenewicz et al., 2007, 2008; Sugimoto et al., 
2008; Pickert et al., 2009). In contrast, other studies have demon-
strated that IL-22 has proinflammatory/pathological properties 
after Toxoplasma gondii infection and in mouse models of psoriasis 
and arthritis (Zheng et al., 2007; Ma et al., 2008; Geboes et al., 
2009; Muñoz et al., 2009).
Although IL-22 is known to induce expression of anti-
microbial peptides after Klebsiella pneumoniae infection in the lung 
(Aujla et al., 2008), the influence of the IL-22 pathway on the   
development, progression, and resolution of airway inflamma-
tion has not yet been examined. Using a model of high-dose 
bleomycin–induced acute tissue damage and airway inflamma-
tion (Snider et al., 1978; Nagai et al., 1992; Huaux et al., 2003; 
Matute-Bello et al., 2008), we demonstrate that a CD4+ Th17 
cell response ensues after treatment of WT mice, characterized 
by the production of IL-22 and IL-17A in the lung. Adminis-
tration of anti–IL-22 neutralizing mAb in WT mice or use of 
Il22/ mice revealed a reduction in bleomycin-induced dis-
ease, indicative of a proinflammatory/pathological role for IL-22 
in airway inflammation. As IL-17A and IL-22 are coexpressed 
and have been shown to act cooperatively (Liang et al., 2006; 
Aujla et al., 2008), we investigated the influence of IL-17A on 
IL-22 expression and function in the lung by using Il17a/ 
mice. Il17a/ mice exhibited enhanced levels of bleomycin-
induced IL-22 expression because of a loss of IL-17A–mediated 
suppression of IL-22 production in Th17 cells. Despite   
increased  IL-22  expression,  Il17a/  mice  were  protected 
from bleomycin-induced airway inflammation, indicating that 
IL-22 acts in synergy with IL-17A to promote airway inflam-
mation. Consistent with this, exogenous IL-22 could only 
promote airway inflammation when coadministered with 
IL-17A. Treatment of Il17a/ mice with anti–IL-22 mAb 
exacerbated  bleomycin-induced  inflammation,  supporting  a 
tissue-protective role for IL-22 in the absence of IL-17A. Fur-
thermore, IL-22 protected airway epithelial cells against bleo-
mycin-induced apoptosis, and this property was reversed with 
the coadministration of IL-17A. Collectively, these data are 
the first to demonstrate a pathological role for IL-22 in a model 
of airway inflammation and identify that IL-17A can govern the 
proinflammatory/pathological versus tissue-protective proper-
ties of IL-22 in the lung.
RESULTS
A Th17 cell response develops during bleomycin-induced 
airway inflammation
When administered at a high dose, bleomycin results in airway 
damage and acute inflammation, characterized by production 
of inflammatory mediators and infiltration of lymphocytes and 
granulocytes, resulting in the disruption of lung architecture, 
decreased pulmonary function, and death (Snider et al., 1978; JEM VOL. 207, June 7, 2010 
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frequency of those that coexpressed 
IL-17A and IL-22 (Fig. 1 E, bottom). 
Collectively, these data demonstrate 
that  after  bleomycin  instillation,  a 
CD4+ Th17 cell response develops 
in WT mice, characterized by ex-
pression  of  IL-17A  and  IL-22  in   
the airway.
Neutralization of IL-22 protects mice  
from bleomycin-induced airway inflammation
IL-22 has proinflammatory and tissue-protective properties in 
several different disease settings (Zenewicz and Flavell, 2008). 
To examine the influence of IL-22 on acute airway damage 
and inflammation, bleomycin-exposed C57BL/6 mice were 
treated with either isotype control or anti–IL-22 neutralizing 
mAb. In comparison to PBS-instilled mice that had a BAL cel-
lularity of 20 × 103 ± 9 × 103, bleomycin-instilled, isotype 
control  mAb–treated  mice  exhibited  a  marked  increase  in   
cellular recruitment to the BAL (Fig. 2 A). Examination and 
differential quantification of hematoxylin and eosin (H&E)–
stained cytocentrifuge BAL preparations isolated from isotype 
control mAb–treated bleomycin-instilled mice revealed that the 
cellular infiltrate was composed of neutrophils (Fig. 2 B, white 
arrows), lymphocytes, and macrophages (Fig. S4 A). In addition, 
a population of Gr-1+ SSChi neutrophils was found in disso-
ciated lung tissue isolated from bleomycin-instilled mice   
(Fig. 2 C). The Gr-1+ cells in the lungs of bleomycin-
treated WT mice were confirmed to be neutrophils, as the 
majority coexpressed CD11b (Fig. S5 A), Ly6C (Fig. S5 B), and 
instillation of high-dose bleomycin. To determine if the 
observed IL-17A+ or IL-22+ CD4+ T cell populations were 
increased after bleomycin exposure, total numbers of cyto-
kine-positive cells in the lungs were quantified. In com-
parison to mice receiving PBS, mice exposed to bleomycin 
exhibited a significant increase in the total number of CD4+ 
T cells that expressed IL-17A or IL-22 (Fig. 1 C), and there 
were significantly elevated levels of IL-17A and IL-22 pro-
tein in supernatants of lung cultures after polyclonal T cell 
stimulation (Fig. 1 D). To examine whether IL-17A and 
IL-22 were coexpressed in CD4+ Th17 cells after exposure 
to bleomycin, TCR+ CD4+ T cells from the bronchioal-
veolar  lavage  (BAL)  and  lung  were  analyzed  by  flow   
cytometry. In comparison to PBS-instilled controls, bleo-
mycin-instilled mice exhibited a significant increase in the 
frequency of TCR+ CD4+ T cells that expressed IL-17A 
alone, IL-22 alone, or coexpressed IL-17A and IL-22 in 
the BAL (Fig. 1 E, top; and Fig. 1 F). Additionally in the 
lung, bleomycin-exposed WT mice exhibited a significant 
increase in the frequency of TCR+ CD4+ T cells that ex-
pressed IL-17A alone, and a trend toward an increase in the 
Figure 1.  A Th17 response develops 
after bleomycin-induced airway inflam-
mation. C57BL/6 mice were intratracheally 
instilled with PBS or bleomycin (Bleo) and 
sacrificed on day 8. (A) cDNA prepared from 
lungs was analyzed by RT-PCR for Il17a and 
Il22 expression. (B) Live lung cells from  
bleomycin-instilled mice were analyzed for 
the frequency of IL-17A+ and IL-22+ T cells.  
Populations are sequentially gated on total 
live cells (left), total cytokine-positive cells  
(middle), and TCR+ cells (right). (C) Total 
numbers of IL-17A+ and IL-22+ CD4+ T cells 
obtained from the lungs of PBS or bleomy-
cin-treated mice. (D) Lung cell suspensions 
were stimulated with anti-CD3 mAb for 48 h, 
and supernatants were analyzed for IL-17A 
and IL-22 secretion by ELISA. (E) CD4+ T cells 
from the BAL and lung cells were analyzed 
for the frequency of IL-17A+ and IL-22+ cells 
by flow cytometry. (F) Frequency from indi-
vidual mice of IL-17A+, IL-22+, and IL-17A+/
IL-22+ CD4+ T cells in the BAL. All data are 
representative of three or more independent 
experiments with a minimum of three to four 
mice per group. Data shown are means ± 
SEM. Significance was determined using the 
Mann-Whitney U test. *, P < 0.05.1296 IL-17 regulates IL-22 function in the lung | Sonnenberg et al.
served by flow cytometric analysis of dissociated 
lung tissue in those mice receiving an anti–IL-22 
neutralizing mAb (Fig. 2 C). Histological analysis 
revealed that blockade of IL-22 also resulted in re-
duced leukocyte recruitment (Fig. 2 D, black arrows) 
and less disruption of lung architecture (Fig. 2 D, 
white arrows). Associated with decreased inflam-
mation, anti–IL-22–treated mice were protected 
from bleomycin-induced weight loss (Fig. 2 E).   
A pathological score combining weight loss and 
histological changes revealed that blockade of IL-22 
significantly  protected  mice  from  bleomycin-
induced pathology (Fig. 2 F).
Consistent with anti–IL-22 mAb treatment of 
WT mice, bleomycin-treated Il22/ mice ex-
hibited a decrease in cell recruitment to the BAL 
(Fig. S6 A), a reduction in airway neutrophilia 
(Fig. S6, B and C), less severe disruption in lung 
architecture  (Fig.  S6  D),  significantly  reduced 
weight loss (Fig. S6 E), and a significant reduction 
in pathology scoring (Fig. S6 F) compared with 
bleomycin-exposed Il22+/+ littermate controls. 
Collectively, these data indicate that IL-22 pro-
duction is pathological in bleomycin-induced air-
way inflammation, promoting inflammatory cell recruitment, 
disruption of lung architecture, and weight loss.
Airway inflammation is reduced in Il17a/ mice despite  
an increase in bleomycin-induced IL-22 expression
IL-22 and IL-17A are coexpressed by Th17 cells, and can act 
cooperatively in the induction of antimicrobial peptides and 
inflammatory mediators (Liang et al., 2006; Aujla et al., 2008). 
To test whether the expression or functions of IL-22 in the 
lung were dependent on the presence of IL-17A, bleomycin 
was instilled into WT and Il17a/ mice. Flow cytometric 
analysis of the BAL revealed a significant increase in the fre-
quency of IL-22+ CD4+ T cells from bleomycin-instilled 
Il17a/ mice compared with WT mice (Fig. 3, A and B). 
Ly6G (Fig. S5 C) and lacked expression of F4/80 (Fig. S5 D) 
and MHCII (Fig. S5 E). Examination of H&E-stained lung 
sections from bleomycin-instilled mice revealed leukocyte 
infiltration (Fig. 2 D, black arrows) and disruption of lung ar-
chitecture (Fig. 2 D, white arrows). Associated with airway 
inflammation, weight loss was observed in bleomycin-instilled 
mice (Fig. 2 E).
In contrast, administration of anti–IL-22 neutralizing mAb 
to bleomycin-exposed mice resulted in a reduction in the total 
number of inflammatory cells infiltrating into the BAL (Fig. 2 A). 
A marked reduction in neutrophilia was observed by mi-
croscopic examination of BAL cell preparations (Fig. 2 B, 
white arrows; and Fig. S4 A), and a significant reduction in 
both the frequency and total number of neutrophils was ob-
Figure 2.  Administration of anti–IL-22 mAb protects 
mice from bleomycin-induced airway inflammation. 
C57BL/6 mice were intratracheally instilled with bleomycin, 
treated with an isotype control (Iso) or anti–IL-22 (IL-22) 
mAb, and sacrificed on day 10. (A) BAL cell counts.  
(B and C) Neutrophil infiltration was assessed by H&E staining 
of BAL cell cytocentrifuge preparations (B; neutrophils are 
highlighted by white arrows) and by flow cytometry of lung 
cells for the frequency (left) and total number (right) of Gr-1+ 
cells (C). Bars, 10 µm. (D) H&E staining of histological lung 
sections demonstrating peribronchial leukocyte infiltrate 
(black arrows) and disruption of lung architecture (white 
arrows). Bars, 100 µm. (E) Weight loss of individual mice was 
plotted as a percentage of starting weight. (F) Total pathology 
score. All data are representative of three or more indepen-
dent experiments with a minimum of three to five mice per 
group. Data shown are means ± SEM. *, P < 0.05; **, P < 0.01.JEM VOL. 207, June 7, 2010 
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chemoattractant Cxcl1 (Fig. S8 A). Consistent with this, in-
stillation of either IL-17A or IL-22 alone did not result in a 
significant increase in the frequency (Fig. S8, B and C) or   
total number (Fig. S8 D) of neutrophils in the BAL or lung. 
In contrast, coadministration of both IL-17A and IL-22 re-
sulted in a significant increase in mRNA expression encoding 
Il6 and Cxcl1 in the lungs of mice (Fig. S8 A). Examination 
of the BAL and lungs revealed that mice receiving coadmin-
istration of both IL-17A and IL-22 exhibited a significant in-
crease in the frequency (Fig. S8, B and C) and total number 
(Fig. S8 D) of neutrophils recruited to the airway. Collec-
tively, these results indicate that in vivo IL-22 alone is not 
proinflammatory in the airway, but IL-22 can act synergisti-
cally with IL-17A to promote expression of inflammatory cyto-
kines and chemokines, leading to the recruitment of neutrophils 
to the airway.
IL-22 is tissue protective in the absence of IL-17A
As Il17a/ mice exhibited elevated levels of IL-22 yet failed to 
develop  bleomycin-induced  inflammation,  we  hypothesized 
that the function of IL-22 in airway inflammation may differ in 
In addition, there were significantly increased levels of IL-22 
in supernatants of polyclonally stimulated lymphocytes isolated 
from the lungs of bleomycin-instilled Il17a/ mice compared 
with WT mice (Fig. 3 C). To test if IL-17A regulates IL-22 
expression, splenocytes were isolated from naive WT or 
Il17a/ mice and polyclonally stimulated under conditions 
permissive for Th17 cell differentiation. There was a marked 
increase in both the frequency and mean fluorescence intensity 
of IL-22+ CD4+ T cells in splenocyte cultures from Il17a/ 
mice compared with WT cultures (Fig. S7 A). Furthermore, 
addition of rIL-17A to splenocyte cultures from Il17a/ mice 
suppressed the frequency and mean fluorescence intensity of 
IL-22+ CD4+ T cells in a dose-dependent manner (Fig. S7 B), 
resulting in a significant decrease in IL-22 protein levels in cul-
ture supernatants (Fig. S7 C). Conversely, IL-22 did not ap-
pear to regulate expression of IL-17A, as bleomycin-instilled 
Il22/ mice produced equivalent levels of IL-17A to WT 
mice (Fig. S7 D), and addition of rIL-22 to splenocyte cultures 
isolated from Il22/ mice did not suppress IL-17A produc-
tion (Fig. S7 E). Collectively, these results indicate that IL-17A 
can inhibit expression of IL-22 in Th17 cells.
Given that the in vivo neutralization of IL-22 reduced 
bleomycin-induced inflammation in WT mice, we hypoth-
esized that the elevated IL-22 levels in bleomycin-instilled 
Il17a/ mice would correlate with exacerbated inflamma-
tion. However, there was a reduction in the cellularity of 
the BAL in Il17a/ mice compared with WT mice after 
bleomycin  instillation  (Fig.  4  A).  Further,  there  was  a 
marked reduction in the bleomycin-induced neutrophil re-
sponses in the BAL of Il17a/ mice compared with WT 
mice (Fig. 4 B, white arrows; and Fig. S4 B), correlating 
with a significant reduction in the frequency and total num-
ber of neutrophils in the lung parenchyma (Fig. 4 C). The 
decreased inflammatory cell recruitment in the BAL and 
lung of Il17a/ compared with WT mice was associated 
with reduced leukocyte infiltrates (Fig. 4 D, black arrows), 
less disruption of lung architecture (Fig. 4 D, white arrows), 
and protection from bleomycin-induced weight loss (Fig. 4 E). 
Pathological scoring confirmed that the absence of IL-17A 
significantly protected mice from bleomycin-induced dis-
ease (Fig. 4 F), thereby demonstrating that abrogation of 
IL-17A also protects mice from bleomycin-induced air-
way inflammation.
Previous studies demonstrated that IL-22 acts synergisti-
cally with IL-17A to promote inflammation and provide pro-
tection  in  the  context  of  infection  with  a  Gram-negative 
pathogen (Aujla et al., 2008), whereas administration of rIL-22 
alone failed to promote neutrophil recruitment into the airway 
(Liang et al., 2007). Therefore, we hypothesized that block-
ade of either IL-17A or IL-22 protected against bleomycin- 
induced disease because the proinflammatory properties of IL-22 
require synergy with IL-17A. To test this hypothesis, we in-
tratracheally instilled rIL-17A alone, rIL-22 alone, or rIL-17A 
and rIL-22 in combination into Il17a/ mice. Instillation of 
either IL-22 alone or IL-17A alone resulted in a significant 
increase in lung expression of Il6 but not of the neutrophil 
Figure 3.  IL-17A partially regulates the expression of IL-22. WT 
and Il17a/ mice were intratracheally instilled with bleomycin and sacri-
ficed on day 10. (A) CD4+ BAL T cells were analyzed for the frequency of 
IL-22+ cells by flow cytometry. (B) Frequency of individual mice for IL-22+ 
CD4+ T cell increases in the BAL. (C) Lung cell suspensions were stimu-
lated with anti-CD3 mAb for 48 h, and supernatants were analyzed for 
IL-22 secretion by ELISA. All data are representative of two or more inde-
pendent experiments with a minimum of three to five mice per group. 
Data shown are means ± SEM. Significance was determined using the 
Mann-Whitney U test. *, P < 0.05.1298 IL-17 regulates IL-22 function in the lung | Sonnenberg et al.
and elevated disruption in lung architecture 
(Fig. 5 D, white arrows) in anti–IL-22–treated 
Il17a/ mice. Epithelial cells in lung tissue ex-
amined from Il17a/ mice in which IL-22 was 
neutralized demonstrated increased hyperplasia 
and loss of normal morphology in comparison to 
isotype control–treated Il17a/ mice after bleo-
mycin administration (Fig. 5 D, gray arrow), 
indicating that IL-22 may influence the integrity 
of the epithelial barrier in the absence of IL-17A. 
Neutralization of IL-22 led to exacerbated 
weight loss in bleomycin-instilled Il17a/ mice 
compared with isotype control–treated Il17a/ 
mice (Fig. 5 E), and pathological scoring con-
firmed  a  significant  increase  in  bleomycin- 
induced inflammation and tissue destruction in 
Il17a/ mice after blockade of IL-22 (Fig. 5 F). 
Blockade of IL-22 in Il17a/ mice established a 
level of bleomycin-induced disease comparable 
to that observed in WT mice, as no statistically 
significant  differences  in  the  BAL  cellularity, 
neutrophil recruitment, weight loss, or pathol-
ogy scoring were observed between bleomycin-
treated WT and anti–IL-22 mAb–treated Il17a/ 
mice (unpublished data). The loss of IL-22–
mediated protection in Il17a/ mice revealed a pathway of 
bleomycin-induced inflammation that was independent of 
both IL-22 and IL-17A. Notwithstanding this, these data indi-
cate that IL-17A may govern the proinflammatory and patho-
logical properties of IL-22 in the lung. Specifically, in the 
presence of IL-17A, IL-22 appears to promote proinflamma-
tory and pathological outcomes, whereas in the absence of 
IL-17A, IL-22 appears to confer a tissue-protective role in this 
model of airway damage and inflammation.
IL-17A regulates IL-22–mediated protection  
from bleomycin-induced airway epithelial cell apoptosis
IL-22 acts on cells of nonhematopoietic origin and has 
been shown to promote epithelial cell repair mechanisms 
the absence of IL-17A. To test this hypothesis, anti–IL-22 neu-
tralizing mAb was administered to bleomycin-instilled Il17a/ 
mice. Consistent with earlier findings (Fig. 4), Il17a/ mice re-
ceiving an isotype control antibody demonstrated minimal signs 
of bleomycin-induced inflammatory cell recruitment (Fig. 5, 
A–C), less disruption in lung architecture (Fig. 5 D), and re-
duced weight loss (Fig. 5 E) compared with WT controls. 
In contrast, administration of anti–IL-22 neutralizing mAb 
to bleomycin-instilled Il17a/ mice resulted in a signifi-
cant increase in cell recruitment to the BAL (Fig. 5 A) and   
correlated with increased neutrophilia in the BAL (Fig. 5 B, 
white arrows; and Fig. S4 C) and lung (Fig. 5 C).
Microscopic  examination  of  H&E-stained  lung  sections 
revealed increased leukocyte infiltration (Fig. 5 D, black arrows) 
Figure 4.  Il17a/ mice are protected from bleo-
mycin-induced pulmonary inflammation. WT or 
Il17a/ mice were intratracheally instilled with bleo-
mycin and sacrificed on day 10. (A) BAL cell counts.  
(B and C) Neutrophil infiltration was assessed by H&E 
staining of BAL cell cytocentrifuge preparations (B; neu-
trophils are highlighted with white arrows) and by flow 
cytometry of lung cells for the frequency (left) and total 
number (right) of Gr-1+ cells (C). Bars, 10 µm. (D) H&E 
staining of histological lung sections demonstrating peri-
bronchial leukocyte infiltrate (black arrows) and disrup-
tion in lung architecture (white arrows). Bars, 100 µm.  
(E) Weight loss of individual mice was plotted as a percent-
age of starting weight. (F) Total pathology score. All data 
are representative of three or more independent experi-
ments with a minimum of three to five mice per group. 
Data shown are means ± SEM. **, P < 0.01; ***, P < 0.001.JEM VOL. 207, June 7, 2010 
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microscopy (Fig. 6 D, middle). These visual altera-
tions correlated with an induction of epithelial cell 
apoptosis, as determined by terminal deoxynucleo-
tidyl trasferase dUTP nick-end labeling (TUNEL) 
staining (Fig. 6 E, middle). However, addition of 
rIL-22 resulted in a striking reduction in bleomycin-
induced disruption of cell morphology (Fig. 6 D, 
right) and decreased epithelial cell apoptosis identi-
fied by TUNEL staining (Fig. 6 E, right). To quan-
tify the IL-22–mediated protection, airway epithelial 
cell cultures were stained with an mAb recognizing 
annexin V and analyzed by flow cytometry. Addi-
tion of rIL-22 significantly protected epithelial cells 
from bleomycin-induced apoptosis (Fig. 6, F and G), 
and this protection was dose dependent (Fig. 6 G). 
IL-22–mediated  protection  was  also  associated 
with significantly increased levels of mRNA tran-
scripts encoding the antiapoptotic genes Bcl2 and 
Bcl2l1 in comparison to cultures that did not re-
ceive IL-22 (Fig. 6 H).
As IL-17A regulated the functional consequences 
of IL-22 expression in vivo, we hypothesized that 
IL-17A may influence IL-22–mediated protection of airway 
epithelial  cells  from  bleomycin-induced  apoptosis  in  vitro. 
Analysis of airway epithelial cells by RT-PCR and ELISA 
revealed the absence of IL-17A expression in PBS- and 
bleomycin-treated airway epithelial cells (unpublished data), 
indicating that there was no source of endogenous IL-17A in 
this system. As observed previously, administration of rIL-22 
protected epithelial cells from bleomycin-induced apoptosis 
(25% increase in protection; Fig. 6 I) compared with PBS con-
trols. However, the addition of exogenous IL-17A to cultures 
enhanced bleomycin-induced apoptosis of airway epithelial cells 
relative to PBS controls (15% decrease in protection; Fig. 6 I). 
Co-administration of rIL-17A and rIL-22 to cultures prevented 
IL-22–mediated protection and instead enhanced bleomycin-
induced apoptosis relative to PBS controls (18% decrease in 
(Wolk et al., 2004; Aujla et al., 2008; Pickert et al., 2009). 
Given that administration of anti–IL-22 neutralizing mAb to 
Il17a/ mice increased bleomycin-induced epithelial cell hy-
perplasia and disruption of lung alveolar architecture (Fig. 5 D, 
gray arrow), we hypothesized that IL-22 may protect epithelial 
cells from bleomycin-mediated damage. To test this, we used 
the mouse pulmonary epithelial cell line MLE-12 (Wikenheiser 
et al., 1993), which expressed Il22ra mRNA transcripts (Fig. 
6 A) and IL-22R protein (Fig. 6 B). Treatment with rIL-22 
led to STAT3 phosphorylation (Fig. 6 C), confirming that this   
cell line is responsive to IL-22. To test whether IL-22 influ-
enced bleomycin-induced damage, bleomycin was added to 
epithelial cell cultures in the presence or absence of rIL-22. 
Administration of bleomycin resulted in disrupted epithelial 
cell morphology and a loss of confluency, as examined by 
Figure 5.  Blockade of IL-22 reverses protection of 
Il17a/ mice from bleomycin-induced pulmonary  
inflammation. Il17a/ mice were intratracheally instilled 
with bleomycin, treated with an isotype control (Iso) or anti–
IL-22 (IL-22) mAb, and sacrificed on day 10. (A) BAL cell 
counts. (B and C) Neutrophil infiltration was assessed by 
H&E staining of BAL cell cytocentrifuge preparations (B; 
highlighted by white arrows) and by flow cytometry of lung 
cells for the frequency (left) and total number (right) of  
Gr-1+ cells (C). Bars, 10 µm. (D) H&E staining of histological 
lung sections demonstrating peribronchial leukocyte infil-
trate (black arrows), disruption in lung architecture (white 
arrows), and epithelial hyperplasia (gray arrow). Bars,  
100 µm. (E) Weight loss of individual mice was plotted as a  
percentage of starting weight. (F) Total pathology score. All 
data are representative of three or more independent  
experiments with a minimum of three to five mice per  
group. Data shown are means ± SEM. *, P < 0.05.1300 IL-17 regulates IL-22 function in the lung | Sonnenberg et al.
To test whether the ability of IL-17A to regulate IL-22–
mediated tissue protection in vivo was associated with altera-
tions  in  epithelial  cell  apoptosis,  TUNEL  staining  was 
protection; Fig. 6 I). Collectively, these results indicate that 
IL-17A regulates the ability of IL-22 to protect airway epi-
thelial cells from bleomycin-induced apoptosis.
Figure 6.  IL-17A regulates the tissue-protective properties of IL-22. (A) cDNA prepared from MLE cells and splenocytes (Spl) was examined for 
the presence of Il22ra transcripts by RT-PCR. (B) Immunoblot of MLE cell and total splenocyte lysates with antibody for IL-22R and -actin. (C) MLE cells 
were stimulated with 10 ng/ml rIL-22 for the indicated times before lysis and immunostaining for phopho-STAT3 (pSTAT3) and total STAT3. (D) For imag-
ing, MLE cell were treated overnight with bleomycin in the absence (Bleo) or presence (+rIL-22) of rIL-22. (E and F) Induction of apoptosis was identified 
by in situ TUNEL staining (E) or flow cytometry analysis for the frequency of annexin V+ cells (F). Bars, 10 µm. (G) Frequency of annexin V+ cells with the 
addition of increasing concentrations of rIL-22. (H) cDNA from bleomycin-treated MLE cells in the presence or absence of 100 ng/ml rIL-22 was prepared 
and analyzed for Bcl2 and Bcl2l1 transcripts by RT-PCR. (I) Percent protection with the addition of 10 ng/ml rIL-17A and 10 ng/ml rIL-22 was determined 
based on the frequency of annexin V+ cells above or below that obtained with bleomycin alone (set at 0). (J) In situ TUNEL staining of paraffin-embedded 
lung tissue. Bars, 10 µm. Data from in vitro studies are representative of two or more independent experiments with triplicate wells per condition. Data 
shown are means ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM VOL. 207, June 7, 2010 
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performed on lung sections of bleomycin-instilled WT and 
Il17a/ mice that were treated with an isotype control or 
with an anti–IL-22 neutralizing antibody. Bleomycin-instilled 
WT mice treated with an isotype control antibody exhibited a 
marked increase in apoptotic bodies in comparison to PBS- 
instilled controls (Fig. 6 J). Consistent with the pathological role 
of IL-22 in bleomycin-induced airway inflammation, blockade 
of IL-22 (WT plus anti–IL-22 mAb) resulted in a reduction of 
bleomycin-induced apoptotic bodies throughout the lung tissue 
(Fig. 6 J). In contrast, blockade of IL-22 in the absence of   
IL-17A (Il17a/ anti–IL-22) demonstrated a marked increase 
in apoptotic bodies compared with isotype-treated controls 
(Fig. 6 J). Collectively, these results indicate that IL-17A gov-
erns the ability of IL-22 to protect airway epithelial cells from 
bleomycin-induced apoptosis in vivo.
DISCUSSION
Although significant advances have been made in characteriz-
ing the expression of IL-22 and IL-22R and the signal trans-
duction  pathways  that  are  activated,  there  are  conflicting 
reports on the biological consequences of IL-22 expression in 
mouse models of inflammation. For example, IL-22 produc-
tion can be either pathological or tissue protective depending 
on the disease model examined (Zenewicz and Flavell, 2008). 
The results of the present study are the first to demonstrate that 
IL-22 expression can promote inflammation after bleomycin-
induced airway inflammation. Critically, the functional out-
comes  of  IL-22  expression  in  the  lung  were  governed  by 
coexpression of IL-17A. When coexpressed in vivo, IL-17A 
and IL-22 acted synergistically to promote chemokine expres-
sion, neutrophil recruitment, and airway inflammation. Con-
versely, in the absence of IL-17A, IL-22 expression was no 
longer proinflammatory and pathological but rather conferred 
tissue-protective functions by promoting the integrity of the 
epithelial barrier. Therefore, differential spatial and temporal 
expression of IL-17A and IL-22 may explain the divergent 
functions of IL-22 reported in different models of infection   
or inflammation.
After bleomycin exposure, a Th17 cell response developed, 
characterized by expression of IL-17A and IL-22 in the lung 
and BAL. Previous studies have identified that many of the 
factors that promote the differentiation of Th17 cells have been 
linked in the pathogenesis of bleomycin-induced airway in-
flammation, including IL-6 and IL-12/23p40 (Maeyama et al., 
2001; Sakamoto et al., 2002; Saito et al., 2008). Consistent 
with a proinflammatory role for Th17 cells, neutralization of 
either Th17 cell–associated effector cytokine, IL-22 or IL-17A, 
was sufficient to provide protection against bleomycin-induced 
airway inflammation in WT mice, suggesting that a functional 
synergy between both cytokines can promote disease. Synergy 
between IL-22 and IL-17A has previously been observed 
in vitro (Liang et al., 2006) and in vivo after infection with the 
pulmonary pathogen K. pneumoniae (Aujla et al., 2008). This 
synergy promoted the production of inflammatory mediators 
and antimicrobial peptides (Liang et al., 2006), and was found 
to be beneficial for the host after pulmonary infection (Aujla   
et al., 2008). However, it was also found that administration of 
exogenous IL-22 itself was not enough to promote neutrophil 
recruitment to the airway (Liang et al., 2007), suggesting that 
IL-17A was required for the proinflammatory properties 
of IL-22. Consistent with this, we demonstrate that exogenous 
IL-22 is only able to promote inflammation in the airway in 
the presence of IL-17A. It is possible that in mouse models of 
psoriasis, arthritis, and protozoan infection, in which IL-22 was 
reported to be proinflammatory (Zheng et al., 2007; Ma et al., 
2008; Geboes et al., 2009; Muñoz et al., 2009), the same 
synergy between IL-22 and IL-17A is operating to pro-
mote inflammation.
In the absence of IL-17A, it was found that there were in-
creased levels of IL-22 after bleomycin instillation. This finding 
was consistent with previous studies that also observed increased 
IL-22 mRNA in the absence of IL-17A in a mouse model of 
colitis (O’Connor et al., 2009) or decreased IL-22 mRNA in 
splenocyte cultures with the addition of exogenous IL-17A 
(Smith et al., 2008; von Vietinghoff and Ley, 2009). In in vitro 
studies, we demonstrated that IL-17A could suppress the ex-
pression and secretion of IL-22 from Th17 cells in a dose- 
dependent manner. Interestingly, it has also been reported that 
IL-17A can inhibit IL-17F expression by Th17 cells (von 
Vietinghoff and Ley, 2009), suggesting a common pathway for 
IL-17A–mediated inhibition of Th17 cell effector cytokine ex-
pression. However, it has not yet been determined whether 
IL-17A is acting directly on the Th17 cells or through an acces-
sory cell, and further investigation must be conducted to deter-
mine the mechanisms through which the suppression of IL-22 
production occurs.
Despite elevated expression of IL-22 in the absence of 
IL-17A, Il17a/ mice were not susceptible to bleomycin- 
induced disease, which is consistent with a loss of the pro-
inflammatory properties of IL-22. However, blockade of IL-22 
in the absence of IL-17A exacerbated bleomycin-induced dis-
ease, indicating a tissue-protective role for IL-22 in airway in-
flammation in the absence of IL-17A. Consistent with this 
hypothesis, we found that rIL-22 could protect airway epithe-
lial cells from bleomycin-induced apoptosis in both in vitro 
and in vivo assays. Further, IL-22–mediated protection from 
epithelial cell apoptosis was reversed in the presence of IL-17A. 
Previous reports proposed a constitutive tissue-protective 
function for IL-22 in mouse models of inflammatory bowel 
disease and hepatitis (Pan et al., 2004; Radaeva et al., 2004; 
Zenewicz et al., 2007, 2008; Sugimoto et al., 2008; Pickert   
et al., 2009). However, after bleomycin-induced airway in-
flammation, IL-22 exhibited a constitutive proinflammatory 
effect in WT mice and was only tissue protective in the 
absence of IL-17A. One possible explanation for the constitu-
tive proinflammatory effects of IL-22 in bleomycin-exposed 
WT mice in comparison to a constitutive tissue-protective role 
for IL-22 reported in mouse models of inflammation in the   
intestine or liver may be the differential coexpression of IL-17A 
and IL-22 in distinct tissues. For example, after bleomycin in-
stillation the majority of IL-22–expressing cells in the lung co-
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(Kotenko et al., 2001; Lejeune et al., 2002; Gaffen, 2009). 
The STAT3 and NF-B pathways regulate a wide range of 
biological processes, including cell growth, differentiation, 
and apoptosis, and complex interactions have been reported 
between these two transcription factors (Alonzi et al., 2001; 
Uskokovic et al., 2007; Bollrath and Greten, 2009). There-
fore, future investigation into the interplay between the signal 
transduction pathways and gene targets of both IL-17A and 
IL-22 will likely yield further insight into the ability of IL-17A 
to regulate the functional consequences of IL-22 expression. 
Notwithstanding this, the results of the present study provide 
the first demonstration that IL-22 can promote disease in a 
model of airway inflammation, and support a model in which 
IL-17A regulates the levels of expression, proinflammatory 
properties, and tissue-protective properties of IL-22, thereby 
determining the functional consequences of IL-22 expression 
in the lung. Differential temporal and spatial coexpression of 
IL-17A and IL-22 may underlie the conflicting reports of the 
biological effects of IL-22 in distinct disease models, and may 
offer selective therapeutic potential in the treatment of Th17 
cell–associated inflammatory diseases.
MATERIALS AND METHODS
Mice, bleomycin instillation, and mAb treatments. C57BL/6 mice 
were purchased from the Jackson Laboratory. C57BL/6 Il17a/ mice were 
provided by Y. Iwakura (University of Tokyo, Tokyo, Japan). 129 Il22/ 
mice were generated at Lexicon Genetics in collaboration with Pfizer and 
subsequently  backcrossed  to  BALB/cBy  at  the  Jackson  Laboratory  with   
colony mates used for all groups. All mice were maintained in specific   
pathogen–free facilities at the University of Pennsylvania. All protocols were 
approved by the University of Pennsylvania Institutional Animal Care and 
Use Committee (IACUC), and all experiments were performed according 
to the guidelines of the University of Pennsylvania IACUC. Bleomycin 
(NOVAPLUS) was administered intratracheally at either a lethal high dose 
of 0.009 mg/g or at a low dose of 0.0018 mg/g. Mice were sacrificed at 8–10 d 
or at reaching 70% of their original weight. Mice receiving antibody treat-
ment were injected i.p. with 0.4 mg of either IL22-01 or an isotype control 
antibody (Pfizer) every 3 d starting on day 0.
Isolation and analysis of lung and BAL cells. BAL cell and lung single-
cell suspensions were obtained as previously described (Nair et al., 2009). 
Cells were stained with antibodies to the following markers: Gr-1, CD11b, 
Ly6G, Ly6C, F4/80, MHCII, CD4, CD8, TCR, and TCR (eBiosci-
ence). For analysis of intracellular cytokine production, cells were stimulated 
directly ex vivo by incubation for 4 h with 50 ng/ml PMA, 750 ng/ml ion-
omycin, and 10 µg/ml brefeldin A (all obtained from Sigma-Aldrich), or 
stimulated for 48 h with soluble anti-CD3 (eBioscience) followed by analy-
sis of cytokine secretion by ELISA. Intracellular staining was performed   
using  FITC-  and  PE-conjugated  IL-17A  antibodies,  Alexa  Fluor  488– 
conjugated IL-17F (eBioscience), and Alexa Fluor 647–conjugated IL22-02 
antibody (Pfizer), with the latter conjugated according to manufacturer’s in-
structions (Invitrogen). Dead cells were excluded from analysis using a violet   
viability  stain  (Invitrogen).  Flow  cytometry  data  collection  was  per-
formed on a FACSCanto II (BD). Files were analyzed using FlowJo software 
(Tree Star, Inc.). Cytocentrifuge preparations of BAL cells were stained with 
H&E (Thermo Fisher Scientific).
RNA isolation, cDNA preparation, and RT-PCR. RNA was isolated 
from whole lung tissue using mechanical homogenization and TRIzol isola-
tion (Invitrogen) according to the manufacturer’s instructions. MLE cell 
RNA was isolated using RNeasy mini kits (QIAGEN). cDNA was generated 
using SuperScript reverse transcriptase (Invitrogen). RT-PCR was performed 
subsets of gut-resident NK cells and skin-resident CD4+ T cells 
are reported to express IL-22 but do not coexpress IL-17A 
(Satoh-Takayama et al., 2008; Cella et al., 2009; Duhen et al., 
2009; Trifari et al., 2009). Collectively, these reports support a 
model in which production of IL-22 by these cell populations 
in the absence of IL-17A may be important in promoting 
tissue-protective  responses.  Therefore,  the  cellular  sources, 
anatomical location, and cytokine coexpression profile of resi-
dent and recruited cell populations may influence the func-
tional properties of IL-22 and provide an explanation for the 
distinct functional roles of IL-22 in models of infection and in-
flammation in distinct peripheral tissues.
When anti–IL-22 mAb was administered in the absence of 
IL-17A, bleomycin-induced disease was comparable to that in 
WT mice and independent of IL-17A and IL-22. It is possible 
that  other  Th17  cell–derived  cytokines  such  as  IL-17F  or 
TNF- may play a significant role in this context, as well as 
other nonrelated inflammatory cytokines such as IFN-, all of 
which have been shown to contribute to airway inflammation 
in other model systems (Lukacs et al., 1995; Segel et al., 2003; 
Liang et al., 2007; Yang et al., 2008). Additionally, a recent re-
port identified that in a model of bleomycin-induced fibrosis, 
IL-17A can act cooperatively with TGF- to promote disease 
(Wilson et al., 2010). In the present study, the influence of 
IL-17A and IL-22 on bleomycin-induced tissue damage and 
acute airway inflammation occurred independently of any sig-
nificant changes in the production of TGF- protein (unpub-
lished data). Notwithstanding that, future studies in a model of 
fibrosis will be required to examine the potential functional 
interactions between IL-17A, IL-22, and TGF- in the devel-
opment and/or progression of disease.
Based on the in vitro and in vivo findings reported here, 
we propose three mechanisms by which IL-17A regulates the 
functional consequences of IL-22 expression. First, IL-17A 
regulates the in vivo and in vitro expression levels of IL-22 by 
inhibiting IL-22 production from Th17 cells. Second, IL-17A 
promotes the proinflammatory properties of IL-22 by acting 
in synergy to induce expression of inflammatory cytokines, 
chemokines, and neutrophil recruitment. Third, IL-17A pre-
vents the tissue-protective functions of IL-22 by suppressing 
the antiapoptotic effects of IL-22 on epithelial cells. There-
fore, this complex regulation of IL-22 by IL-17A may underlie 
how IL-22 can promote both pathological or tissue-protective 
outcomes depending on the context in which it is expressed.
The ability of IL-22 to be either pathological or protec-
tive, depending on the context in which it is expressed, is 
a property shared by other cytokines that signal through 
STAT3, including IL-6 and IL-27, which can either promote 
or regulate inflammation dependent on the cytokine milieu 
and regulation of signal transduction (Yasukawa et al., 2003; 
Villarino et al., 2004). It is probable that the interplay be-
tween IL-17A and IL-22 signaling pathways will determine 
the balance between proinflammatory versus tissue-protec-
tive outcomes. IL-22 is known to signal through the STAT3 
and p38 mitogen-activated protein kinase pathways, whereas 
IL-17A signals predominantly through the NF-B pathway JEM VOL. 207, June 7, 2010 
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protein is not up-regulated after administration of high-dose bleomycin. 
Fig.  S3  shows  that  IL-17F  protein  is  not  up-regulated  after  administra-
tion of high-dose bleomycin. Fig. S4 displays the differential BAL counts 
in different experimental treatment groups after administration of bleomy-
cin. Fig. S5 shows that the phenotype of infiltrating Gr-1+ SSChi cells after 
bleomycin instillation is consistent with that of neutrophils. Fig. S6 dem-
onstrates that Il22/ mice are protected from bleomycin-induced airway 
inflammation. Fig. S7 demonstrates that IL-17A regulates IL-22 expression 
in Th17 cells but IL-22 does not regulate IL-17A expression. Fig. S8 dem-
onstrates that IL-17A and IL-22 act synergistically to promote airway in-
flammation. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20092054/DC1.
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on cDNA using SYBR green chemistry (Applied Biosystems) and commer-
cially available primer sets (QIAGEN). Reactions were run on an RT-PCR 
system (ABI7500; Applied Biosystems). Samples were normalized to -actin 
and displayed as fold induction over naive or untreated controls unless other-
wise stated.
Histological sections and pathology scoring. Lungs were inflated with 
4% paraformaldehyde and embedded in paraffin, and 5-µm sections were used 
for staining with H&E. The severity of bleomycin-induced pathology was 
scored according to weight loss (1, 1–10%; 2, 10–15%; 3, 15–20%; 4, 20–25%; 
and 5, 25–30%) and blind scoring of H&E-stained lung tissue sections accord-
ing to consolidation (1–5), fibrosis (1–5), granulocyte recruitment (1–5), and 
lymphocyte recruitment (1–5), for an overall score out of 25.
ELISA and Immunofluorescence staining. Standard IL-17A sandwich 
ELISAs were performed using commercially available antibodies (eBiosci-
ence). Sandwich ELISAs for IL-22 were performed using IL22-01 (Pfizer) as a 
capture antibody and biotin-conjugated IL22-03 (Pfizer) as a detection anti-
body. Active TGF- was measured from lung homogenates as previously de-
scribed (Huaux et al., 2003) using a commercially available ELISA kit 
(eBioscience). Immunofluorescence staining was performed as previously de-
scribed (Nair et al., 2009) using a commercially available antibody for TGF- 
(Santa Cruz Biotechnology, Inc.).
Instillation of recombinant cytokines. rIL-17A (eBioscience) and rIL-22 
(Pfizer) in sterile PBS were administered intratracheally to Il17a/ mice 
daily over a 3-d period at a dose of 1 µg/mouse. Mice were sacrificed on day 
4 for analysis of the BAL and lung.
In vitro splenocyte activation. Single-cell suspensions were obtained from 
spleens of mice and red blood cells were lysed. Splenocytes were cultured with 
1 µg/ml of soluble anti-CD3 and anti-CD28 (eBioscience) in the presence of 
10 ng/ml rIL-6, 1 ng/ml rTGF-, 10 ng/ml rIL-23, 10 µg/ml anti–IL-4, and 
10 µg/ml anti–IFN-. rIL-17A and rIL-22 were added to cultures at the des-
ignated concentrations. After 3–5 d of stimulation, cells were restimulated with 
PMA and ionomycin in the presence of BFA for 4 h, followed by staining for 
intracellular cytokines.
Electrophoresis and immunostaining. Analysis was performed using 
standard SDS-PAGE and immunoblotting techniques. Biotin-conjugated 
anti–IL-22R1 (R&D Systems), anti-actin, anti–phospho-STAT3 (Tyr705), 
and total anti-STAT3 (Cell Signaling Technology) were used as primary anti-
bodies, followed by either streptavidin-conjugated horseradish peroxidase 
(R&D Systems) or donkey anti–rabbit–conjugated streptavidin (GE Health-
care). Blots were developed using ECL detection reagents (GE Healthcare).
MLE cell line and in vitro apoptosis assay. The MLE cell line (American 
Type Culture Collection) was a gift from M.F. Beers (University of Pennsylva-
nia, Philadelphia, PA) and maintained in RPMI 1640 media supplemented with 
2% FBS, 5 µg/ml insulin, 10 µg/ml transferrin, 20 nM sodium selenite, 10 nM 
hydrocortisone, 10 nM -estradiol, 10 mM Hepes, and 2 mM l-glutamine. 
After seeding and adherence, apoptosis was induced by administration of 
2.5 U/ml bleomycin to cultures or PBS as a control. rIL-22 or rIL-17A was 
added to cultures at designated concentrations and incubated for 8 h before 
harvesting using 0.05% trypsin-EDTA. Cell suspensions were subsequently 
stained for annexin V according to the manufacturer’s protocols (BD). Cell 
cultures and paraffin-embedded lung sections were stained using the TMR 
Red In Situ Cell Death Detection Kit (Roche) according to the manufactur-
er’s protocol.
Statistical analysis. Results represent means ± SEM. Statistical significance 
was determined by the Student’s t test unless otherwise noted in the figure 
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